The Generic Medicines Industry Association has welcomed the announcement from member company, Hospira, that its biosimilar infliximab (Inflectra) is now available in more major European markets, including Austria, Denmark, France, Germany, Greece, Italy, Luxembourg, Netherlands, Spain and Sweden.
This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.
No Comment